At a glance · 47 peptides · 9 goals
At a glance
Every peptide, grouped by what people use it for, ranked by evidence grade. A peptide can appear under more than one goal. The dose column shows only label or trial ranges, each with its route and source; Reddit dose reports are on the peptide pages.
Sleep Falling asleep, sleep depth and sleep quality.
- B Oral
It activates the receptor used by ghrelin, a hormone involved in hunger and growth hormone release.
Trial 25 mg daily (one fixed dose) · route: Oral · source
- C Subcutaneous injection
It has been studied as a sleep-related signal, but small human trials did not establish reliable sleep improvement.
Trial 25 nmol/kg intravenously on three afternoons in the 1992 insomnia trial · route: IV · source
- C Subcutaneous injection
It activates the ghrelin receptor and can stimulate growth hormone release.
Trial 0.03 mg/kg intravenously twice daily for up to seven days or discharge after bowel surgery · route: IV · source
- C Subcutaneous injection
It stimulates the gland below the brain to release growth hormone.
Trial DAC form: single subcutaneous doses of 30–250 micrograms/kg; a separate multiple-dose study used 20–60… · route: Subcutaneous injection · source
- C Subcutaneous injection
Laboratory studies suggest interactions with material that controls gene activity.
No label or trial dose range
- C Subcutaneous injection
It stimulates the gland below the brain to release growth hormone.
Trial 30 micrograms/kg subcutaneously once daily for up to one year in GH-deficient children · route: Subcutaneous injection · source
- C Subcutaneous injection
Laboratory studies report effects on protective chromosome ends, without proving longer life in people.
Trial 0.5 mg/day sublingually for 20 days, night-shift biomarker study · route: Sublingual · source
- D Subcutaneous injection
This naturally occurring peptide is associated with the energy-producing parts of cells.
No label or trial dose range
Recovery & injury Tendons, joints, injuries, wound healing and recovery from training.
- B IM injection
It contains a mixture of small protein fragments and amino acids from pig brains.
Trial 30 mL/day IV for 10 days (CASTA); 30 mL/day for 21 days with rehabilitation (CARS) · route: IV · source
- C Subcutaneous injection
It activates the ghrelin receptor and can stimulate growth hormone release.
Trial 0.03 mg/kg intravenously twice daily for up to seven days or discharge after bowel surgery · route: IV · source
- C Subcutaneous injection
Cell and animal experiments suggest effects on signals involved in blood vessel growth and tissue repair.
Trial start 10 · typical 10–20 mg · max 20 mg, daily for two consecutive days · route: IV · source
- C Subcutaneous injection
It stimulates the gland below the brain to release growth hormone.
Trial DAC form: single subcutaneous doses of 30–250 micrograms/kg; a separate multiple-dose study used 20–60… · route: Subcutaneous injection · source
- C Subcutaneous injection
It is designed to activate a cell signal involved in limiting injury and inflammation.
Trial start 1 · typical 1–8 mg · max 8 mg, daily · route: Subcutaneous injection · source
- D Subcutaneous injection
It reduced some inflammatory signals in cell and animal experiments.
No label or trial dose range
- D Subcutaneous injection
TB-500 is a fragment associated with thymosin beta-4, so findings from the full protein may not apply.
No label or trial dose range
- D Subcutaneous injection
This natural immune peptide can disrupt some microbes in laboratory experiments.
Trial 0.5 or 1.6 mg/mL, equivalent to 12.5 or 40 micrograms/cm², twice weekly for 13 weeks · route: Topical · source
- D Oral
Dihexa was proposed to affect a cell growth pathway, but a key supporting paper was retracted.
No label or trial dose range
- D Subcutaneous injection
Follistatin binds proteins that normally limit muscle growth, but injected products lack proven enhancement benefits.
Trial 3 × 10^11–6 × 10^11 vector genomes/kg/leg, delivered to quadriceps in the Becker muscular dystrophy study · route not stated in the source · source
- D Subcutaneous injection
GHK-Cu binds copper, but topical or laboratory findings do not establish benefits from this injected blend.
No label or trial dose range
- D Subcutaneous injection
It is a modified growth factor that activates signals involved in cell growth.
No label or trial dose range
- D Subcutaneous injection
GHK-Cu binds copper, but effects of the complete mixture have not been established in people.
No label or trial dose range
- D IM injection
Claims about muscle repair come largely from experiments on related growth-factor fragments.
No label or trial dose range
Fat loss Body weight, belly fat, appetite and blood sugar.
- A Subcutaneous injection
It activates GLP-1 receptors that help reduce appetite and food intake.
Approved label start 0.25 · typical 1.7–2.4 mg · max 7.2 mg, once weekly · route: Subcutaneous injection · source
- A Subcutaneous injection
It activates GLP-1 and GIP receptors and helps reduce food intake.
Approved label start 2.5 · typical 5–15 mg · max 15 mg, once weekly · route: Subcutaneous injection · source
- B Subcutaneous injection
It activates hormone receptors involved in fullness and food intake.
Trial start 1 · typical 1–12 mg · max 12 mg, once weekly · route: Subcutaneous injection · source
- B Subcutaneous injection
It stimulates the gland below the brain to release growth hormone.
Approved label 1.28 mg daily (one fixed dose) · route: Subcutaneous injection · source
- B Subcutaneous injection
It mimics amylin, a hormone that helps the brain recognize fullness.
Trial start 0.3 · typical 0.3–4.5 mg · max 4.5 mg, once weekly · route: Subcutaneous injection · source
- C Subcutaneous injection
It activates the ghrelin receptor and can stimulate growth hormone release.
Trial 0.03 mg/kg intravenously twice daily for up to seven days or discharge after bowel surgery · route: IV · source
- C Subcutaneous injection
It stimulates the gland below the brain to release growth hormone.
Trial DAC form: single subcutaneous doses of 30–250 micrograms/kg; a separate multiple-dose study used 20–60… · route: Subcutaneous injection · source
- C Subcutaneous injection
It stimulates the gland below the brain to release growth hormone.
Trial 30 micrograms/kg subcutaneously once daily for up to one year in GH-deficient children · route: Subcutaneous injection · source
- D Oral
- D Subcutaneous injection
Human growth hormone fragment 176–191
It is a small piece of growth hormone with a different sequence from AOD-9604.
No label or trial dose range
- D Subcutaneous injection
Experiments suggest it affects signals that help cells respond to energy shortages.
No label or trial dose range
- D Subcutaneous injection
It is a modified growth factor that activates signals involved in cell growth.
No label or trial dose range
- F Subcutaneous injection
This modified growth hormone fragment was designed around fat breakdown seen in animal experiments.
Trial start 0.25 · typical 0.25–1 mg · max 1 mg, daily · route: Oral · source
Cognition & mood Focus, memory, anxiety and mood.
- B IM injection
It contains a mixture of small protein fragments and amino acids from pig brains.
Trial 30 mL/day IV for 10 days (CASTA); 30 mL/day for 21 days with rehabilitation (CARS) · route: IV · source
- C IV
It stimulates the brain signal that helps control reproductive hormones.
Trial 0.01–3 micrograms/kg intravenous boluses; 1.5–4 micrograms/kg/hour infusions in separate 2011 experiments · route: IV · source
- C Nasal spray
Laboratory studies suggest changes in signaling related to anxiety, but the human mechanism is uncertain.
Trial 2.7 mg/day with phenazepam for 14 days; 20 adjunct-arm participants continued Selank for 7 further days;… · route not stated in the source · source on the peptide page
- C Nasal spray
Animal studies report changes in proteins involved in nerve-cell growth and survival.
Trial 6 mg daily total during treatment courses (one fixed dose) · route not stated in the source · source
- C IV
Nicotinamide adenine dinucleotide, oxidized form
NAD is a molecule cells use to transfer energy during normal chemical reactions.
Trial 10 mg daily (one fixed dose) · route: IV · source
- C Subcutaneous injection
Laboratory studies suggest interactions with material that controls gene activity.
No label or trial dose range
- D Nasal spray
In laboratory tests it blocks a channel that helps control nerve-cell electrical activity.
No label or trial dose range
- D Nasal spray
The name Adamax does not identify a consistently verified chemical product.
No label or trial dose range
- D Oral
Dihexa was proposed to affect a cell growth pathway, but a key supporting paper was retracted.
No label or trial dose range
- D Subcutaneous injection
This naturally occurring peptide is associated with the energy-producing parts of cells.
No label or trial dose range
Libido & sexual health Desire, erections and sex hormones.
- A Subcutaneous injection
It activates several receptors involved in signals such as pigmentation and sexual responses.
Approved label 1.75 mg as needed, no more than once per 24 hours (one fixed dose) · route: Subcutaneous injection · source
- C IV
It stimulates the brain signal that helps control reproductive hormones.
Trial 0.01–3 micrograms/kg intravenous boluses; 1.5–4 micrograms/kg/hour infusions in separate 2011 experiments · route: IV · source
- C Subcutaneous injection
It activates receptors involved in making skin pigment.
Trial 0.01–0.03 mg/kg subcutaneously in the three-person phase 1 escalation study · route: Subcutaneous injection · source
Longevity Anti-ageing, mitochondria and healthy ageing claims.
- C Subcutaneous injection
It binds a fat called cardiolipin in the inner membrane of the energy-producing parts of cells.
Approved label 40 mg daily (one fixed dose) · route: Subcutaneous injection · source
- C Topical
This small protein fragment binds copper and may influence copper-related cell processes.
Trial 0.4% topical copper-tripeptide cream in venous-ulcer RCT · route: Topical · source
- C Oral
This family contains different short peptides and tissue extracts that cannot be treated as one drug.
Trial Thymalin 10 mg intramuscularly daily for 10 days per course in one 2003 study program · route: IM injection · source on the peptide page
- C IV
Nicotinamide adenine dinucleotide, oxidized form
NAD is a molecule cells use to transfer energy during normal chemical reactions.
Trial 10 mg daily (one fixed dose) · route: IV · source
- C Subcutaneous injection
Laboratory studies report effects on protective chromosome ends, without proving longer life in people.
Trial 0.5 mg/day sublingually for 20 days, night-shift biomarker study · route: Sublingual · source
- C Oral
It blocks a cell pathway that responds to nutrients and promotes growth.
Trial start 5 · typical 5–10 mg · max 10 mg, once weekly · route: Oral · source
- C Topical
It is designed to interfere with nerve signals involved in facial muscle contraction.
Trial 0.03% SNAP-8 in a patch also containing 5% ascorbyl glucoside and 4% sodium cyclic lysophosphatidic acid;… · route: Topical · source
- C IM injection
It contains a mixture of protein fragments extracted from calf thymus tissue.
Trial 10 mg daily (one fixed dose) · route: IM injection · source
- D Subcutaneous injection
Experiments suggest it affects signals that help cells respond to energy shortages.
No label or trial dose range
- D Subcutaneous injection
In laboratory models it disrupts a protein interaction that helps some aged cells survive.
No label or trial dose range
- D Subcutaneous injection
This naturally occurring peptide is associated with the energy-producing parts of cells.
No label or trial dose range
Skin & hair Wrinkles, skin repair, tanning and hair growth.
- C Topical
This small protein fragment binds copper and may influence copper-related cell processes.
Trial 0.4% topical copper-tripeptide cream in venous-ulcer RCT · route: Topical · source
- C Subcutaneous injection
It activates receptors involved in making skin pigment.
Trial 0.01–0.03 mg/kg subcutaneously in the three-person phase 1 escalation study · route: Subcutaneous injection · source
- C Topical
It is designed to interfere with nerve signals involved in facial muscle contraction.
Trial 0.03% SNAP-8 in a patch also containing 5% ascorbyl glucoside and 4% sodium cyclic lysophosphatidic acid;… · route: Topical · source
- D Subcutaneous injection
It reduced some inflammatory signals in cell and animal experiments.
No label or trial dose range
- D Topical
- D Subcutaneous injection
GHK-Cu binds copper, but topical or laboratory findings do not establish benefits from this injected blend.
No label or trial dose range
- D Subcutaneous injection
GHK-Cu binds copper, but effects of the complete mixture have not been established in people.
No label or trial dose range
Immune Infections, immune support and inflammation-related immune claims.
- B Subcutaneous injection
It can affect signals that control how immune cells respond.
Trial 1.6 mg every 12 hours (one fixed dose) · route: Subcutaneous injection · source
- C Nasal spray
Laboratory studies suggest changes in signaling related to anxiety, but the human mechanism is uncertain.
Trial 2.7 mg/day with phenazepam for 14 days; 20 adjunct-arm participants continued Selank for 7 further days;… · route not stated in the source · source on the peptide page
- C IM injection
It contains a mixture of protein fragments extracted from calf thymus tissue.
Trial 10 mg daily (one fixed dose) · route: IM injection · source
- C Nasal spray
It can relax blood vessels, with temporary lung-vessel effects observed in a small inhalation study.
Trial 100 mcg two administrations 30 minutes apart once daily (one fixed dose) · route: Inhaled · source
- D Subcutaneous injection
This natural immune peptide can disrupt some microbes in laboratory experiments.
Trial 0.5 or 1.6 mg/mL, equivalent to 12.5 or 40 micrograms/cm², twice weekly for 13 weeks · route: Topical · source
Muscle & strength Lean mass, strength and growth hormone for body composition.
- B Oral
It activates the receptor used by ghrelin, a hormone involved in hunger and growth hormone release.
Trial 25 mg daily (one fixed dose) · route: Oral · source
- C Subcutaneous injection
It activates the ghrelin receptor and can stimulate growth hormone release.
Trial 0.03 mg/kg intravenously twice daily for up to seven days or discharge after bowel surgery · route: IV · source
- C Subcutaneous injection
It stimulates the gland below the brain to release growth hormone.
Trial DAC form: single subcutaneous doses of 30–250 micrograms/kg; a separate multiple-dose study used 20–60… · route: Subcutaneous injection · source
- C Subcutaneous injection
It stimulates the gland below the brain to release growth hormone.
Trial 30 micrograms/kg subcutaneously once daily for up to one year in GH-deficient children · route: Subcutaneous injection · source
- D Subcutaneous injection
Follistatin binds proteins that normally limit muscle growth, but injected products lack proven enhancement benefits.
Trial 3 × 10^11–6 × 10^11 vector genomes/kg/leg, delivered to quadriceps in the Becker muscular dystrophy study · route not stated in the source · source
- D Subcutaneous injection
It is a modified growth factor that activates signals involved in cell growth.
No label or trial dose range
- D IM injection
Claims about muscle repair come largely from experiments on related growth-factor fragments.
No label or trial dose range
Grades rate the evidence for the use people buy each substance for, not its safety. User reports are anecdata, not evidence: self-selected, unverified, often combined with other compounds.